Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.

The elicitation of broadly neutralizing antibodies directed against the human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins, gp120 and gp41, remains a major challenge. Attempts to utilize monomeric gp120 as an immunogen to elicit high titers of neutralizing antibodies have been disappointing. Envelope glycoprotein constructs that better reflect the trimeric structure of the functional envelope spike have exhibited improved immunogenicity compared with monomeric gp120. We have described soluble gp140 ectodomain constructs with a heterologous trimerization motif; these have previously been shown to elicit antibodies in mice that were able to neutralize a number of HIV-1 isolates, among them primary isolate viruses. Recently, solid-phase proteoliposomes retaining the envelope glycoproteins as trimeric spikes in a physiologic membrane setting have been described. Here, we compare the immunogenic properties of these two trimeric envelope glycoprotein formulations and monomeric gp120 in rabbits. Both trimeric envelope glycoprotein preparations generated neutralizing antibodies more effectively than gp120. In contrast to monomeric gp120, the trimeric envelope glycoproteins elicited neutralizing antibodies with some breadth of neutralization. Furthermore, repeated boosting with the soluble trimeric formulations resulted in an increase in potency that allowed neutralization of a subset of neutralization-resistant HIV-1 primary isolates. We demonstrate that the neutralization is concentration-dependent, is mediated by serum IgG and that the major portion of the neutralizing activity is not directed against the gp120 V3 loop. Thus, mimics of the trimeric envelope glycoprotein spike described here elicit HIV-1-neutralizing antibodies that could contribute to a protective immune response and provide platforms for further modifications to improve the efficiency of this process.

[1]  E. Fenyö,et al.  Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization. , 1997, Virology.

[2]  D. Montefiori,et al.  ANTIBODY-DEPENDENT ENHANCEMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION , 1988, The Lancet.

[3]  P. Earl,et al.  Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities , 1994, Journal of virology.

[4]  J. Mascola,et al.  Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T Cells , 2002, Journal of Virology.

[5]  J. Sodroski,et al.  Highly Stable Trimers Formed by Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Fused with the Trimeric Motif of T4 Bacteriophage Fibritin , 2002, Journal of Virology.

[6]  J. Sodroski,et al.  Stabilization of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers by Disulfide Bonds Introduced into the gp41 Glycoprotein Ectodomain , 1998, Journal of Virology.

[7]  J. Sodroski,et al.  Characterization of Stable, Soluble Trimers Containing Complete Ectodomains of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins , 2000, Journal of Virology.

[8]  J. Levy,et al.  The FC and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. , 1989, Disease markers.

[9]  W A Hendrickson,et al.  Energetics of the HIV gp120-CD4 binding reaction. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Mascola,et al.  Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.

[11]  M. Champe,et al.  Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160 , 1990, Nature.

[12]  Q. Sattentau,et al.  HIV-1 antibody — debris or virion? , 1997, Nature Medicine.

[13]  K. Sikora,et al.  Human monoclonal antibodies. , 1984, Nature.

[14]  Abraham Pinter,et al.  Human Monoclonal Antibodies Specific for Conformation-Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus Type 1 Primary Isolates from Various Clades , 2002, Journal of Virology.

[15]  J. Sodroski,et al.  Improved Elicitation of Neutralizing Antibodies against Primary Human Immunodeficiency Viruses by Soluble Stabilized Envelope Glycoprotein Trimers , 2001, Journal of Virology.

[16]  F. Ennis,et al.  Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. , 1988, Science.

[17]  J. Mascola,et al.  Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. , 1996, The Journal of infectious diseases.

[18]  D. Montefiori,et al.  Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. , 1997, The Journal of infectious diseases.

[19]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[20]  D. Ho,et al.  High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[21]  H. Schuitemaker,et al.  Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera , 1995, Journal of virology.

[22]  C. Barbas,et al.  Determinants of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Activation by Soluble CD4 and Monoclonal Antibodies , 1998, Journal of Virology.

[23]  J. Sodroski,et al.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.

[24]  J. Sodroski,et al.  Solid-Phase Proteoliposomes Containing Human Immunodeficiency Virus Envelope Glycoproteins , 2002, Journal of Virology.

[25]  J. Sodroski,et al.  CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization , 1998, Journal of Virology.

[26]  Ying Sun,et al.  Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates , 1995, Journal of virology.

[27]  K. Steimer,et al.  Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. , 1997, Vaccine.

[28]  J. Binley,et al.  A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure , 2000, Journal of Virology.

[29]  D. Montefiori,et al.  Induction of immune responses to HIV‐1 by canarypox virus (ALVAC) HIV‐1 and gp120 SF‐2 recombinant vaccines in uninfected volunteers , 1998, AIDS.

[30]  J. Sodroski,et al.  Modifications That Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution , 2000, Journal of virology.

[31]  A. Trkola,et al.  Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex , 1997, Journal of virology.

[32]  J. Hansen,et al.  Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection , 1995, Journal of virology.

[33]  Peter D. Kwong,et al.  HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.

[34]  Q. Sattentau,et al.  Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer , 1995, The Journal of experimental medicine.

[35]  J. Heeney,et al.  HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. , 1994, Vaccine.

[36]  D R Burton,et al.  A model for neutralization of viruses based on antibody coating of the virion surface. , 2001, Current topics in microbiology and immunology.

[37]  J. Moore,et al.  Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates , 1992, Journal of virology.

[38]  J. Mascola,et al.  Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. , 1994, The Journal of infectious diseases.

[39]  J. Kappes,et al.  Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes , 1991, Journal of virology.

[40]  D R Burton,et al.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.

[41]  C. Cheng‐Mayer,et al.  Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.

[42]  A. Trkola,et al.  Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines , 1998, Journal of Virology.

[43]  K. Yoon,et al.  Antibody-dependent enhancement of virus infection and disease. , 2003, Viral immunology.